Author:
Muso Eri,Mune Masatoshi,Hirano Tsutomu,Hattori Motoshi,Kimura Kenjiro,Watanabe Tsuyoshi,Yokoyama Hitoshi,Sato Hiroshi,Uchida Shunya,Wada Takashi,Shoji Tetsuo,Yuzawa Yukio,Takemura Tsukasa,Sugiyama Satoshi,Nishizawa Yoshiki,Ogahara Satoru,Yorioka Noriaki,Sakai Soichi,Ogura Yosuke,Yukawa Susumu,Iino Yasuhiko,Imai Enyu,Matsuo Seiichi,Saito Takao
Publisher
Springer Science and Business Media LLC
Subject
Physiology (medical),Nephrology,Physiology
Reference21 articles.
1. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2:1309–11.
2. Buemi M, Nostro L, Crasci E, Barilla A, Cosentini V, Aloisi C, Sofi T, Campo S, Frisina N. Statins in nephrotic syndrome: a new weapon against tissue injury. Med Res Rev. 2005;25:587–609.
3. Ito S, Machida H, Inaba A, Harada T, Okuyama K, Nakamura T, Aihara Y, Yokota S. Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin. Pediatr Nephrol. 2007;22:603–6.
4. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 1985;5:613–22.
5. Tojo K, Sakai S, Miyahara T. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Jpn J Nephrol. 1988;30:1153–60.